Core Insights - The event on June 24 marked a significant collaboration between the Chinese Academy of Sciences and Guangxi, showcasing 240 major scientific achievements aimed at addressing Guangxi's urgent needs in key sectors like artificial intelligence, high-end equipment manufacturing, and advanced new materials [1][2] - A total of 25 projects reached cooperation intentions, with a signed total amount of 88.75 million yuan, highlighting the successful partnerships formed during the event [1] - The event featured 21 key projects that were signed on-site, including advancements in robotics and biotechnology, demonstrating the potential for innovation in various fields [1] Group 1: Event Overview - The event was the first large-scale, systematic collaboration between the Chinese Academy of Sciences and Guangxi, focusing on technology transfer [1] - The theme of the event was "Chinese Academy of Sciences enters Guangxi, creating a future," aiming to deepen technological innovation cooperation [2] Group 2: Key Projects and Technologies - Notable projects included the development of a bionic brain chip for robots and advanced gene editing techniques for organ transplantation, showcasing cutting-edge technology [1] - The event also highlighted new technologies for environmentally friendly and efficient rare earth mining [1] Group 3: Financial Support and Collaboration - The Guangxi Technology Achievement Transformation Fund was introduced to provide financial support for the transformation of scientific achievements into production [2] - The event facilitated a platform for in-depth analysis of strengths and cooperation needs between local enterprises and research institutes [2]

眉山未来产业基金正式启动，基金规模为5亿元，由眉山市产业引导基金、四川省科技创新投资集团和彭 山区共同发起设立，主要投资低空经济、新型储能、生物制造等前沿产业领域。当前，眉山市依托交通 区位优势、优越的空域条件、丰富的旅游资源，成功跻身四川省低空经济试点城市。 榜单： 「2025投资机构软实力排行榜」评选启动 峰会： 「2025母基金年度论坛」盛大启幕：汇聚中国力量！ 热文： 一纸新规，炸出一级市场的管理费焦虑 热文： 今年，上市公司热衷做并购基金 此次未来基金的设立，正是锚定低空经济赛道，抢抓低空经济产业密集创新和高速增长的战略机遇，基 金将聚焦空域试点、低空制造业和人才培养三大领域，助力低空经济产业项目在眉落地生根，打造西南 地区低空制造协同配套高地，加快提升我市低空经济竞争力。 未来，眉山产投私募基金公司将进一步发挥基金撬动作用，引导更多社会资本支持眉山战略性新兴行业 和未来产业发展，持续培育壮大新兴产业和加快布局未来产业，推动低空经济等未来产业在眉山实现技 术突破、应用场景拓展和产业集群发展。 来源：眉山投资控股集团 对接需求请扫码 每日｜荐读 ...

特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 SynBioCon 大会 | 生物制造青年论坛 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

精英计划-人才需求 | 天津工生所 中国科学院天津工业生物技术研究所是由中国科学院与天津市人民政府共建、整建制从事生物制造和 工业生物技术研究的国立科研机构，是我国工业生物领域的战略科技力量，肩负着创新生物产业关键 核心技术、发展生物制造重大颠覆性技术、支撑我国生物经济高质量可持续发展的历史使命，围 绕"以可再生碳资源替代化石资源、以清洁生物加工方式替代传统化学加工方式、以现代生物技术提 升产业水平"三大战略主题，重点开展"工业蛋白质科学与生物催化工程、合成生物学与微生物制造 工程、生物系统与生物工艺工程"三个领域方向的基础研究和应用基础研究。 招 聘部门 简介 01 邓子新大师工作室以活性天然产物的创新与绿色制造为目标，遵循"师从于自然、认知于自然，创新 于自然"的学术思路，运用合成生物学理念，聚焦交叉学科前沿，建立和完善天然药物精准发掘、结 构创新和优产新模式，实现微生物天然药物的高效生产。 团队由 徐敏研究员 与 侯安伟研究员 领衔，重点关注全新作用机制抗生素（糖肽抗生素）与萜类天 然产物的高效精准挖掘、生物合成机制与作用机制解析以及相关新分子的高效创制。 徐敏研究员主要从事微生物天然产物合成生物学以及 ...

6月20日，工业和信息化部党组书记、部长李乐成主持召开第十次中小企业圆桌会议。会上，来自量子 科技、人工智能、人形机器人、生物制造等未来产业领域的10家初创期中小企业负责人介绍了技术研 发、人才引育、投融资支持、场景应用等方面情况，结合各自生产经营中遇到的困难和挑战，提出政策 举措建议。李乐成强调，我国中小企业有灵气、有活力，发展未来产业前景广阔、大有可为。希望大家 树立雄心壮志，加强前沿技术和颠覆性技术突破，打造原创技术策源地，加快产出标志性产品、形成引 领性标准。要坚持走专精特新发展道路，聚焦细分领域苦练内功，不断提高企业质量、效益和核心竞争 力。要大力弘扬企业家精神，坚定发展信心，保持战略定力，用足用好国家各类支持政策，乘势而上， 当好前行者、开拓者，为发展新质生产力、推进新型工业化积极贡献力量。(工信微报) ...

Core Viewpoint - The company reported a significant increase in overseas revenue for 2024, driven primarily by the growth in amino acid product sales and the introduction of new products, despite a decline in overall gross margin due to competitive pricing pressures in the market [2][18]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][3]. - The main contributors to the overseas revenue growth were the amino acid series products, particularly L-valine, and the vitamin series products, which saw increased sales volumes [5][18]. - The company’s overseas sales were primarily concentrated in Europe (41.58%), the Americas (28.51%), and Asia & others (29.91%) [3][4]. Group 2: Gross Margin Analysis - The overall gross margin for the company in 2024 was reported at 24.92%, a decrease of 15.60 percentage points compared to the previous year [18]. - The gross margin for amino acid products was 30.00%, down 13.32 percentage points, while the vitamin products experienced a more significant decline [18][19]. - The decline in gross margin was attributed to lower average selling prices for key products such as L-valine and myo-inositol, which saw price drops of 17.89% and 54.09% respectively [19][20]. Group 3: Future Outlook and Industry Trends - The demand for amino acids is expected to continue growing due to trends in precision nutrition and the reduction of traditional feed ingredients like soybean meal [23][24]. - The global market for biosynthetic vitamins is projected to grow significantly, with a compound annual growth rate of 9.32% from 2024 to 2030, driven by advancements in synthetic biology [24]. - The company is positioned to benefit from its technological advantages in fermentation processes, which are more environmentally friendly and cost-effective compared to traditional methods [27][28].

第二届合成生物学与生物制造应用大会 九大活动精彩安排 | | 第二届合成生物学与生物制造应用大会 日程安排 | | --- | --- | | 6月19日 上午 | 开幕+主题报告 | | 6月19日 下午 | 未来食品与功效物质开发智造智用专题 | | 6月19日 下午 | SCC细胞健康产业专题 | | 6月20日 上午 | AI+合成生物制造创新发展专题 | | 6月20日 上午 | 精准开发与产业创新专题 | | 6月20日 上午 | 生物医药产业专题暨留・在光明-光明留学人员嘉年华 | | 6月20日 下午 | 大健康与美妆产业智造智用专题 | | 6月20日 下午 | 传统产业与新生物制造交叉创新专题 | | 6月20日 下午 | 创新项目投融资路演 | 免费报名通道 第二届合成生物学与生物制造应用大会 时间: 2025年6月19-20日 上 午 9:00-18:00 地点: 中国·深圳·光明区·卫光生命科学园一楼学术报告厅（导航：卫光生命科学园） 扫码免费报名参会 详细会议流程 大咖嘉宾6月19-20日 相约鹏城 育成绩 物理 www.ziang with and and and and and ...

Core Viewpoint - The article emphasizes the development of the biomanufacturing industry in Hubei Province, which is seen as a key future industry as outlined in the 2025 government work report, aiming to transform small microorganisms into large-scale industries [1]. Group 1: Agricultural Biomanufacturing - Hubei Fubon Technology Co., Ltd. is focusing on innovative agricultural biopreparations, developing new biodegradable coating agents and soil restoration agents to enhance grain yield [2]. - The company's core product, "biostimulants," acts as a "lubricant" and "amplifier" in agricultural production, improving the efficiency of pesticides and fertilizers [4]. - The research team led by Professor Chen Shouwen from Hubei University has developed a biostimulant using Bacillus licheniformis, showcasing advantages in bioprocessing and broad applications [4]. Group 2: Industrial Microbial Strains - Industrial microbial strains are considered the "chips" of biomanufacturing, with over 80% of core industrial strains in China being dependent on foreign sources [6]. - Research on the strain "Pseudomonas putida" has shown its potential to convert agricultural waste into ethanol, presenting a sustainable alternative to traditional methods that rely on food crops [8]. - Wuhan Ruijia Kang Biotechnology Co., Ltd., founded by Professor Yang Shihui, has developed cellulose ethanol and D-lactic acid, with plans to achieve a production scale of 100,000 tons within five years [8]. Group 3: Collaborative Innovation - Hubei Province is building a collaborative system involving government, industry, academia, and finance to accelerate the development of biomanufacturing [9]. - Hubei University has established partnerships with companies like Angel Yeast to create a joint innovation platform for synthetic biology and modern biomanufacturing [10]. - The provincial government is addressing technology demands across various sectors to promote high-quality development in the synthetic biology industry during the 14th Five-Year Plan [12].

Core Insights - The recent breakthrough in AI enzyme design by MoleculeMind and Hong Kong Polytechnic University has been recognized at the ICML 2025 conference, marking a significant advancement in the field of AI enzyme design [1] - The traditional methods of enzyme discovery and optimization are time-consuming and costly, with a success rate of less than 1%, highlighting the urgent need for innovative solutions in the biomanufacturing sector [2] - The introduction of the SENZ method, which utilizes substrate structure similarity for enzyme design, represents a novel approach that could revolutionize enzyme generation [3][5] Industry Overview - Enzymes are crucial for the development of the trillion-dollar bio-economy, impacting sectors such as biomedicine, green chemistry, and environmental degradation [1] - The lack of ideal biocatalysts is a major barrier to scaling production in the biomanufacturing industry, leading to annual capacity losses exceeding $100 billion in pharmaceuticals, chemicals, and agriculture [2] - AI protein design has emerged as a promising solution to generate precise catalysts by learning from existing enzyme structure-function relationships, although it faces challenges with novel synthetic molecules due to limited training data [2] Company Developments - MoleculeMind has developed the SENZ method, which integrates biological data retrieval and generative AI to create enzymes without direct catalytic data, thus addressing a critical challenge in enzyme generation [3][5] - The SENZ method has demonstrated superior performance compared to traditional enzyme design methods, potentially providing tailored solutions for complex drug synthesis and environmental remediation [6] - MoleculeMind is expanding its capabilities in "on-demand design" across various fields, including antibodies, vaccines, and industrial enzymes, aiming to provide innovative biological solutions for health, environmental, and sustainability challenges [7]